ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag big pharma neuroscience microbiology

Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Start It Up
Dan Cossins | Apr 1, 2013 | 8 min read
Young researchers who left the academic path to transform their bright ideas into thriving companies discuss their experiences, and how you can launch your own business.
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Bianca Nogrady | Oct 1, 2019 | 9 min read
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
Nanotech Dreams
Jeffrey Perkel | Mar 3, 2002 | 9 min read
Nanotechnology hit the big time in July 1995, when it debuted on the television show, The Outer Limits. In an episode entitled "The New Breed," a scientist develops nanorobots capable of repairing damaged cells and correcting physical defects. But, like any good morality play, the experiment goes horribly wrong, turning a panacea into a nightmare. Clearly, nanotechnology makes for good science fiction, but scientists have been working to make it an interesting reality, too. Nanotechnology refers
Sons of Next Gen
Tia Ghose | Jun 1, 2012 | 8 min read
New innovations could bring tailored, fast, and cheap sequencing to the masses.
The Heart of Europe's Biotech Sector
Martina Habeck | Aug 1, 2004 | 6 min read
More than 5,000 scientists with higher academic degrees work in public research in Europe's Upper Rhine valley, making this area one of the highest densities of life sciences-related research in the world. Now, the triangle region from Basel, Switzerland, in the south to Strasbourg, France, and Freiburg, Germany, in the north is striving to become the European heart of the biotechnology sector.The Dreiländereck or la Régio, as the region is called locally, has a lot going for it: excel
Alzheimer Research Joins the Mainstream
Christine Bahls | Jan 20, 2002 | 5 min read
In 1977, Alzheimer Disease researcher Peter Davies spoke with some neurologists about his work, which he began a year earlier. "One [neurologist] said, 'This is lovely..., but why don't you work on something that is more common?'" he remembers. Davies says the comment epitomized scientists' then-dismissive attitude about Alzheimer Disease (AD). When Alois Alzheimer first identified this memory-destroying disorder in 1907, his patient was a 50-year-old woman; a very early age, as researchers now
Automated Colony Pickers Evolve
Helen Dell(hdell@the-scientist.com) | Jul 3, 2005 | 6 min read
Everyone knows that the first genome sequencing projects took years of work and represent the combined product of tens of thousands of individual fragments.
Porcine Possibilities
Ricki Lewis | Oct 15, 2000 | 8 min read
Courtesy of PPL TherapeuticsA new generation of pigs. Headlines in late summer 2000 introduced long-awaited reports on pig cloning and retroviral transmission to mice, pig cells healing rat spinal cords, and a gaff by Dolly dad Ian Wilmut erroneously heralding halt of xenograft work at the Roslin Institute near Edinburgh, Scotland. So it seemed that the question of whether pigs can pass their retroviruses to humans might finally be on the road to resolution. Not quite. Pigs, as the purveyors o

Run a Search

ADVERTISEMENT